Qiagen Nv Medical Equipment: Ken Research
Qiagen NV (QIA) - Medical Equipment - Deals and Alliances Profile

Qiagen NV (QIA) - Medical Equipment - Deals and Alliances Profile


  • Products Id :- GDME2456D
  • |
  • Pages: 147
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company offers consumable products, instruments and automation systems. The company's sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue; assay technologies to identify the genetic information of a pathogen in a tumor; bioinformatics solutions to analyze and interpret genomic data; and solutions to automate the use of consumables into efficient molecular testing workflows. It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical and biotechnology and life sciences research markets. The company offers its products through subsidiaries and a network of independent distributors. It has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Qiagen is headquartered in Venlo, the Netherlands.

Qiagen NV (QIA)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 8

Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 9

Qiagen NV, Medical Equipment Deals By Type, 2012 to YTD 2018 10

Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 11

Qiagen NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 12

Qiagen NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 13

Qiagen NV, Medical Equipment, Deal Details 18

Asset Purchase 18

QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 18

Venture Financing 19

ArcherDX Raises USD35 Million in Series A Financing 19

Exosome Diagnostics Raises USD60 Million in Series B Financing Round 20

Protagen Raises USD12.5 Million in Venture Financing 22

Curetis Raises USD18 Million in Extended Series B Venture Financing 23

Exosome Diagnostics Raises USD 27 Million In Series B Financing Round 25

Drug Response Dx Raises Funds Through First Round Of Venture Financing 27

Xagenic Raises USD 10 Million In Series A Venture Financing 28

Partnerships 29

Qiagen Enters into Licensing Agreement with Johns Hopkins University 29

QIAGEN Enters into Licensing Agreement with Johns Hopkins University 30

Qiagen Enters into Licensing Agreement with MDxHealth 31

Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 32

Qiagen Enters Into Option For Licensing Agreement With Columbia University For FGFR-TACC Fusion Genes 33

Qiagen Enters Into Option For Licensing Agreement With BC Cancer For EZH2 Y641 Mutation Biomarker 34

IntelligentMDx Enters Into Licensing Agreement with Qiagen To Develop Molecular Tests 35

Qiagen Enters Into Licensing Agreement With Drug Response Dx For Rheumatoid Arthritis Biomarkers 36

Qiagen Enters Into Licensing Agreement With Insight Genetics For Lung Cancer Biomarkers 37

Qiagen Enters Into Licensing Agreement With Inserm Transfert For Colorectal Cancer Biomarker 38

Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 39

QIAGEN Enters Into Licensing Agreement With Personal Genome Diagnostics 40

Qiagen Enters into Partnership with Freenome 41

QIAGEN Enters into Agreement with Natera 42

Biomillenia Enters into Agreement with Qiagen 43

Qiagen and Centogene Enter into Co-Marketing Agreement 44

ANGLE Enters into Co-Marketing Agreement with Qiagen 45

DiaSorin Enters into Agreement with QIAGEN 46

Qiagen Forms Joint Venture with Maccura Biotech 47

ArcherDX and HeliTec Enter into Partnership 48

Singulex Enters into Agreement with Qiagen 49

Sophia Genetics Enters into Agreement with Qiagen 50

Sophia Genetics Enters into Agreement with ArcherDx 51

SeraCare Life Sciences Enters into Agreement with ArcherDx 52

Qiagen Enters into Agreement with Genohm 53

ArcherDx Enters into Partnership with PierianDx 54

ArcherDX Enters into Co-Development Agreement with Illumina 55

CareDx to Partner with Qiagen 56

Qiagen Enters into Partnership with Therawis Diagnostics 57

CosmosID Enters into Agreement with Qiagen 58

NanoString Technologies Enters into Co-Development Agreement with HalioDx 59

Qiagen Enters into Agreement with 10X Genomics 60

Qiagen Enters into Co-Development Agreement with Array BioPharma 61

ArcherDX Enters into Co-Marketing Agreement with GenomOncology 62

Qiagen Forms Joint Venture with Biotype Diagnostics 63

Qiagen Enters into Agreement with Hitachi High-Technologies 64

Qiagen Enters into Agreement with GATC Biotech 65

Tokai Pharma Expands Agreement with Qiagen 66

Qiagen Enters into Distribution Agreement with Altona Diagnostics for RealStar Ebolavirus RT-PCR Kit 1.0 67

Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 68

Qiagen Enters into Co-Development Agreement with Novartis 69

Qiagen Enters into Co-Development Agreement with Astellas Pharma 70

AstraZeneca Enters into Co-Development Agreement with Qiagen 71

Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 72

Maverix Biomics Extends Co-Marketing Agreement With Qiagen 73

Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 74

Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 75

Maverix Biomics Enters Into Co-Marketing Agreement With Qiagen 76

Clovis Oncology Enters Into Co-Development Agreement With Qiagen 77

Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 79

Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 80

Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 82

PrimeraDx Enters Into Co-Development Agreement With Quest Diagnostics 83

Ingenuity Systems Enters Into Agreement With GeneInsight To Deliver Integrated Workflow Solution To Clinical Labs 84

Qiagen Enters Into Co-Development Agreement With Eli Lilly 85

Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 86

Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In Oncology 87

Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 88

Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 89

PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 90

Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular Diagnostic Products 91

Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 92

QIAGEN Enters Into Co-Development Agreement With Insight Genetics 93

QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 94

Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 95

Inserm Transfert Enters into Licensing Agreement with HalioDx 96

Transgenomic Expands Licensing Agreement with Exiqon 97

Equity Offering 98

Exiqon Completes Private Placement Of Shares For USD 2.6 Million 98

Debt Offering 99

Qiagen Raises USD400 Million in Private Placement of Notes 99

Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 100

Qiagen Completes Public Offering Of Senior Notes Due 2019 For USD 430 Million 101

Qiagen Completes Public Offering Of Senior Notes Due 2021 For USD 300 Million 102

Exiqon Completes Private Placement Of Bonds For USD 3 Million 103

Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 104

Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 105

Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 106

Asset Transactions 107

Cryopak Industries Acquires LaunchWorks Manufacturing Lab from ArcherDX 107

Diatherix Labs Acquires Tem-PCR Patent From Qiagen 108

Acquisition 109

Qiagen Acquires STAT-Dx 109

Qiagen Acquires OmicSoft 110

Qiagen Acquires Exiqon for up to USD102.4 Million 111

Qiagen Acquires MO BIO Labs 113

Qiagen Acquires PrimeraDx, Molecular Diagnostic Company 114

Qiagen Acquires CLC bio 115

Enzymatics Acquires ArcherDx, Diagnostic Technology Provider, For USD 50 Million 116

Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 117

Qiagen NV-Key Competitors 118

Qiagen NV-Key Employees 119

Qiagen NV-Locations And Subsidiaries 120

Head Office 120

Other Locations & Subsidiaries 120

Joint Venture 123

Recent Developments 124

Financial Announcements 124

May 02, 2018: QIAGEN Announces First Quarter 2018 Financial Results 124

Jan 31, 2018: QIAGEN Reports Results for Fourth Quarter and Full-year 2017, Announces STAT-Dx Acquisition and New $200 Million Share Repurchase 127

Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017 132

May 02, 2017: QIAGEN reports results for first quarter 2017 135

Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016 137

Government and Public Interest 141

Mar 30, 2017: QIAGEN joins CANCER-ID consortium for liquid biopsy workflows 141

Product News 142

Nov 15, 2017: QIAGEN advances precision medicine by automating guidelines on cancer variants in industry-leading QIAGEN Clinical Insight software 142

Apr 03, 2017: QIAGEN’s GeneReader NGS System gains further validation in oncology research applications with new independent performance review data 143

Other Significant Developments 144

Feb 07, 2018: QIAGEN and Sentieon Partner to Advance Precision Medicine With Highly Efficient Variant-Calling Software 144

Jan 08, 2018: QIAGEN adds to Growth Momentum in Next-Generation Sequencing with 2018 Plans for Significant Portfolio Enhancements 145

Jan 30, 2017: QIAGEN Hereditary and Rare Disease Solution Chosen by Genomics England 146

Appendix 147

Methodology 147

About GlobalData 147

Contact Us 147

Disclaimer 147

List of Figures

Qiagen NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Qiagen NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 9

Qiagen NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 10

Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 11

Qiagen NV, Medical Equipment, Deals by Market, 2012 to YTD 2018 12

List of Tables

Qiagen NV, Medical Equipment, Key Facts, 2017 2

Qiagen NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Qiagen NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 9

Qiagen NV, Medical Equipment Deals By Type, 2012 to YTD 2018 10

Qiagen NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 11

Qiagen NV, Deals By Market, 2012 to YTD 2018 12

Qiagen NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 13

QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 18

ArcherDX Raises USD35 Million in Series A Financing 19

Exosome Diagnostics Raises USD60 Million in Series B Financing Round 20

Protagen Raises USD12.5 Million in Venture Financing 22

Curetis Raises USD18 Million in Extended Series B Venture Financing 23

Exosome Diagnostics Raises USD 27 Million In Series B Financing Round 25

Drug Response Dx Raises Funds Through First Round Of Venture Financing 27

Xagenic Raises USD 10 Million In Series A Venture Financing 28

Qiagen Enters into Licensing Agreement with Johns Hopkins University 29

QIAGEN Enters into Licensing Agreement with Johns Hopkins University 30

Qiagen Enters into Licensing Agreement with MDxHealth 31

Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 32

Qiagen Enters Into Option For Licensing Agreement With Columbia University For FGFR-TACC Fusion Genes 33

Qiagen Enters Into Option For Licensing Agreement With BC Cancer For EZH2 Y641 Mutation Biomarker 34

IntelligentMDx Enters Into Licensing Agreement with Qiagen To Develop Molecular Tests 35

Qiagen Enters Into Licensing Agreement With Drug Response Dx For Rheumatoid Arthritis Biomarkers 36

Qiagen Enters Into Licensing Agreement With Insight Genetics For Lung Cancer Biomarkers 37

Qiagen Enters Into Licensing Agreement With Inserm Transfert For Colorectal Cancer Biomarker 38

Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 39

QIAGEN Enters Into Licensing Agreement With Personal Genome Diagnostics 40

Qiagen Enters into Partnership with Freenome 41

QIAGEN Enters into Agreement with Natera 42

Biomillenia Enters into Agreement with Qiagen 43

Qiagen and Centogene Enter into Co-Marketing Agreement 44

ANGLE Enters into Co-Marketing Agreement with Qiagen 45

DiaSorin Enters into Agreement with QIAGEN 46

Qiagen Forms Joint Venture with Maccura Biotech 47

ArcherDX and HeliTec Enter into Partnership 48

Singulex Enters into Agreement with Qiagen 49

Sophia Genetics Enters into Agreement with Qiagen 50

Sophia Genetics Enters into Agreement with ArcherDx 51

SeraCare Life Sciences Enters into Agreement with ArcherDx 52

Qiagen Enters into Agreement with Genohm 53

ArcherDx Enters into Partnership with PierianDx 54

ArcherDX Enters into Co-Development Agreement with Illumina 55

CareDx to Partner with Qiagen 56

Qiagen Enters into Partnership with Therawis Diagnostics 57

CosmosID Enters into Agreement with Qiagen 58

NanoString Technologies Enters into Co-Development Agreement with HalioDx 59

Qiagen Enters into Agreement with 10X Genomics 60

Qiagen Enters into Co-Development Agreement with Array BioPharma 61

ArcherDX Enters into Co-Marketing Agreement with GenomOncology 62

Qiagen Forms Joint Venture with Biotype Diagnostics 63

Qiagen Enters into Agreement with Hitachi High-Technologies 64

Qiagen Enters into Agreement with GATC Biotech 65

Tokai Pharma Expands Agreement with Qiagen 66

Qiagen Enters into Distribution Agreement with Altona Diagnostics for RealStar Ebolavirus RT-PCR Kit 1.0 67

Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 68

Qiagen Enters into Co-Development Agreement with Novartis 69

Qiagen Enters into Co-Development Agreement with Astellas Pharma 70

AstraZeneca Enters into Co-Development Agreement with Qiagen 71

Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 72

Maverix Biomics Extends Co-Marketing Agreement With Qiagen 73

Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 74

Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 75

Maverix Biomics Enters Into Co-Marketing Agreement With Qiagen 76

Clovis Oncology Enters Into Co-Development Agreement With Qiagen 77

Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 79

Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 80

Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 82

PrimeraDx Enters Into Co-Development Agreement With Quest Diagnostics 83

Ingenuity Systems Enters Into Agreement With GeneInsight To Deliver Integrated Workflow Solution To Clinical Labs 84

Qiagen Enters Into Co-Development Agreement With Eli Lilly 85

Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 86

Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In Oncology 87

Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 88

Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 89

PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 90

Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular Diagnostic Products 91

Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 92

QIAGEN Enters Into Co-Development Agreement With Insight Genetics 93

QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 94

Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 95

Inserm Transfert Enters into Licensing Agreement with HalioDx 96

Transgenomic Expands Licensing Agreement with Exiqon 97

Exiqon Completes Private Placement Of Shares For USD 2.6 Million 98

Qiagen Raises USD400 Million in Private Placement of Notes 99

Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 100

Qiagen Completes Public Offering Of Senior Notes Due 2019 For USD 430 Million 101

Qiagen Completes Public Offering Of Senior Notes Due 2021 For USD 300 Million 102

Exiqon Completes Private Placement Of Bonds For USD 3 Million 103

Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 104

Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 105

Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 106

Cryopak Industries Acquires LaunchWorks Manufacturing Lab from ArcherDX 107

Diatherix Labs Acquires Tem-PCR Patent From Qiagen 108

Qiagen Acquires STAT-Dx 109

Qiagen Acquires OmicSoft 110

Qiagen Acquires Exiqon for up to USD102.4 Million 111

Qiagen Acquires MO BIO Labs 113

Qiagen Acquires PrimeraDx, Molecular Diagnostic Company 114

Qiagen Acquires CLC bio 115

Enzymatics Acquires ArcherDx, Diagnostic Technology Provider, For USD 50 Million 116

Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 117

Qiagen NV, Key Competitors 118

Qiagen NV, Key Employees 119

Qiagen NV, Subsidiaries 120

Qiagen NV, Joint Venture 123

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Qiagen NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com